Effect of a novel tetrapeptide derivative in a model of isoproterenol induced myocardial necrosis.
Isoproterenol hydrochloride (ISO), a beta adrenergic agonist, is known to cause ischemic necrosis in rats. Cardiotoxicity of three different doses of ISO were studied using physiological, biochemical and histopathological parameters. The effects of single and double dose of ISO were analysed, which illustrated that single ISO dose was more cardiotoxic than double ISO dose due to ischemic preconditioning. The tetrapeptide derivatives L-lysine-L-arginine-L-aspartic acid-L-serine (tetrapeptide A) and di-tert.butyloxycarbonyl-L-lysine-L-arginine-L-aspartic acid-tert.butyl O-tert.butyl-L-serinate (tetrapeptide B) along with acetylsalicylic acid as positive control were analysed at different time points for their cardioprotective effect. The results demonstrated that optimal protective effects were observed by pretreatment with 5 mg/kg of tetrapeptide B and this was found to be slightly better than that of acetylsalicylic acid. A lesser degree of cardioprotection was noticed when low doses of tetrapeptide B were administered. This study clearly showed that single dose of ISO (50 mg/kg, s.c.) induced myocardial necrosis could be used as a model to assess cardiovascular drugs and in this model, it was demonstrated that the tetrapeptide B could exhibit optimal cardioprotective effect.
Ramesh
C V
CV
Department of Biotechnology, Central Leather Research Institute, Adyar, Madras, India.
Malarvannan
P
P
Jayakumar
R
R
Jayasundar
S
S
Puvanakrishnan
R
R
D000318:Adrenergic beta-Agonists / Q000633:toxicity; D000818:Animals; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use; D001835:Body Weight / Q000187:drug effects; D003402:Creatine Kinase / Q000032:analysis; D004195:Disease Models, Animal; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006470:Hemorrhage; D007545:Isoproterenol / Q000008:administration & dosage / Q000633:toxicity*; D007770:L-Lactate Dehydrogenase / Q000032:analysis; D007781:Lactoferrin / Q000494:pharmacology* / Q000627:therapeutic use; D017202:Myocardial Ischemia / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D009206:Myocardium / Q000473:pathology*; D009336:Necrosis; D009842:Oligopeptides / Q000494:pharmacology* / Q000627:therapeutic use; D009929:Organ Size / Q000187:drug effects; D010446:Peptide Fragments / Q000494:pharmacology* / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
D000318:Adrenergic beta-Agonists; D009842:Oligopeptides; D010446:Peptide Fragments; D010975:Platelet Aggregation Inhibitors; C115985:tetrapeptide B; C056549:KRDS peptide; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase; D007781:Lactoferrin; D007545:Isoproterenol; D001241:Aspirin